Which patients presenting with arthralgia eventually develop rheumatoid arthritis? The current state of the art

Research output: Contribution to journalArticlepeer-review

Standard

Which patients presenting with arthralgia eventually develop rheumatoid arthritis? The current state of the art. / Raza, Karim.

In: RMD Open, Vol. 2017, No. 3, e000479, 14.11.2017.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{d2c2c766d410456bbde9f8a8e5a84444,
title = "Which patients presenting with arthralgia eventually develop rheumatoid arthritis? The current state of the art",
abstract = "Early initiation of treatment in patients with inflammatory arthritis at risk of persistence and/or erosive progression is important because it is associated with a reduced rate of progression of joint damage and functional disability. It hasbeen proposed that a window of opportunity exists, during which disease processes are less matured and disease modification can be more effective. The phase of arthralgia preceding clinical arthritis is likely to be an important partof this window of opportunity, during which treatment might prevent progression to clinical arthritis. Several proof-of-concept trials in individuals with arthralgia are now evaluating this hypothesis. Central to such trials is the ability to identify groups at high risk of rheumatoid arthritis (RA) in whom preventive treatment can be tested. This review describes the relevance of adequate predictionmaking, as well as the accuracy of different types of predictors (including imaging and serological markers) with their value in predicting the progression of arthralgia to arthritis. Despite promising results, studies have beenperformed in heterogeneous patient populations and most findings have not been validated in independent studies. Future observational or preventive studies should be conducted with homogeneous patient groups (eg, patientsfulfilling the European League Against Rheumatism criteria for arthralgia at risk of RA) in order to increase interstudy comparability and to allow result validation.",
author = "Karim Raza",
year = "2017",
month = nov,
day = "14",
doi = "10.1136/rmdopen-2017-000479",
language = "English",
volume = "2017",
journal = "RMD Open",
issn = "2056-5933",
publisher = "BMJ Publishing Group",
number = "3",

}

RIS

TY - JOUR

T1 - Which patients presenting with arthralgia eventually develop rheumatoid arthritis? The current state of the art

AU - Raza, Karim

PY - 2017/11/14

Y1 - 2017/11/14

N2 - Early initiation of treatment in patients with inflammatory arthritis at risk of persistence and/or erosive progression is important because it is associated with a reduced rate of progression of joint damage and functional disability. It hasbeen proposed that a window of opportunity exists, during which disease processes are less matured and disease modification can be more effective. The phase of arthralgia preceding clinical arthritis is likely to be an important partof this window of opportunity, during which treatment might prevent progression to clinical arthritis. Several proof-of-concept trials in individuals with arthralgia are now evaluating this hypothesis. Central to such trials is the ability to identify groups at high risk of rheumatoid arthritis (RA) in whom preventive treatment can be tested. This review describes the relevance of adequate predictionmaking, as well as the accuracy of different types of predictors (including imaging and serological markers) with their value in predicting the progression of arthralgia to arthritis. Despite promising results, studies have beenperformed in heterogeneous patient populations and most findings have not been validated in independent studies. Future observational or preventive studies should be conducted with homogeneous patient groups (eg, patientsfulfilling the European League Against Rheumatism criteria for arthralgia at risk of RA) in order to increase interstudy comparability and to allow result validation.

AB - Early initiation of treatment in patients with inflammatory arthritis at risk of persistence and/or erosive progression is important because it is associated with a reduced rate of progression of joint damage and functional disability. It hasbeen proposed that a window of opportunity exists, during which disease processes are less matured and disease modification can be more effective. The phase of arthralgia preceding clinical arthritis is likely to be an important partof this window of opportunity, during which treatment might prevent progression to clinical arthritis. Several proof-of-concept trials in individuals with arthralgia are now evaluating this hypothesis. Central to such trials is the ability to identify groups at high risk of rheumatoid arthritis (RA) in whom preventive treatment can be tested. This review describes the relevance of adequate predictionmaking, as well as the accuracy of different types of predictors (including imaging and serological markers) with their value in predicting the progression of arthralgia to arthritis. Despite promising results, studies have beenperformed in heterogeneous patient populations and most findings have not been validated in independent studies. Future observational or preventive studies should be conducted with homogeneous patient groups (eg, patientsfulfilling the European League Against Rheumatism criteria for arthralgia at risk of RA) in order to increase interstudy comparability and to allow result validation.

U2 - 10.1136/rmdopen-2017-000479

DO - 10.1136/rmdopen-2017-000479

M3 - Article

VL - 2017

JO - RMD Open

JF - RMD Open

SN - 2056-5933

IS - 3

M1 - e000479

ER -